Compare
ADMA Biologics, Inc. vs Immunocore Holdings plc vs Twist Bioscience Corp vs Repligen Corp
| Latest fiscal year | ADMA Biologics, Inc. ADMA | Immunocore Holdings plc IMCR | Twist Bioscience Corp TWST | Repligen Corp RGEN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-09-30 | 2025-12-31 |
| Revenue | $510.17M | $400.02M | $376.57M | $738.26M |
| Revenue growth (YoY) | +19.6% | +29.0% | +20.3% | +16.4% |
| Gross margin | 57.4% | n/a | 50.7% (computed) | 52.3% (computed) |
| Operating margin | 37.5% | -11.3% | -36.2% | 7.5% |
| Net margin | 28.8% | -8.9% | -20.6% | 6.6% |
| Net income | $146.93M | -$35.51M | -$77.67M | $48.89M |
| EPS (Diluted) | $0.60 | -$0.71 | -$1.30 | $0.86 |
| Operating cash flow | $50.40M | -$10.71M | -$47.63M | $117.42M |
| Free cash flow | $27.82M | -$15.05M | -$75.63M | $93.90M |
| Cash & equivalents | $87.63M | $467.71M | $183.05M | $566.02M |
| Total assets | $624.24M | $1.07B | $641.86M | $2.95B |
| Total liabilities | $146.92M | $686.24M | $168.90M | $843.57M |
| Shareholders' equity | $477.32M | $381.03M | $472.96M | $2.11B |
| Return on year-end equity | 30.8% | -9.3% | -16.4% | 2.3% |
| Shares outstanding | 237.87M | 50.69M | 60.63M | 56.33M |
Revenue, most recent five fiscal years
| Fiscal year | ADMA Biologics, Inc. | Immunocore Holdings plc | Twist Bioscience Corp | Repligen Corp |
|---|---|---|---|---|
| Latest | $510.17M Ended 2025-12-31 | $400.02M Ended 2025-12-31 | $376.57M Ended 2025-09-30 | $738.26M Ended 2025-12-31 |
| 1 year earlier | $426.45M Ended 2024-12-31 | $310.20M Ended 2024-12-31 | $312.97M Ended 2024-09-30 | $634.44M Ended 2024-12-31 |
| 2 years earlier | $258.21M Ended 2023-12-31 | $249.43M Ended 2023-12-31 | $245.11M Ended 2023-09-30 | $632.36M Ended 2023-12-31 |
| 3 years earlier | $154.08M Ended 2022-12-31 | $174.36M Ended 2022-12-31 | $203.56M Ended 2022-09-30 | $801.54M Ended 2022-12-31 |
| 4 years earlier | $80.94M Ended 2021-12-31 | $36.48M Ended 2021-12-31 | $132.33M Ended 2021-09-30 | $670.53M Ended 2021-12-31 |